key: cord-0926769-1iaozno5
authors: Kalra, Rajkumar Singh; Kandimalla, Ramesh
title: Engaging the spikes: heparan sulfate facilitates SARS-CoV-2 spike protein binding to ACE2 and potentiates viral infection
date: 2021-01-29
journal: Signal Transduct Target Ther
DOI: 10.1038/s41392-021-00470-1
sha: b3f313e8330082879c4eef7453beee1d19b4ab30
doc_id: 926769
cord_uid: 1iaozno5

nan

residues in the plain font). Lan et al. 2 earlier showed that the Asn487, Tyr489, Gln493, Tyr449, Gly446, Thr500, Asn501, Gly502, and Lys417 residues in the S-protein RBD are engaged in ACE2 recognition and binding (Fig. 1b , inset-ACE2-binding site). Hence, it corroborated that the adjacent loci of RBD can bind to HS and ACE2 simultaneously, yet in a cooperative manner. Given the early RBD to HS binding, HS facilitates the initial SARS-CoV-2 virion docking to the host cell, yet the viral entry requires its subsequent transfer to a protein receptor. These results emphasized the role of HS as a "virus collector", given its direct engagement with virus particles at the cell membrane and subsequently facilitating the open RBD conformation (Fig. 1c, d) . It further explains that how besides the ACE2 expression level, HS greatly exhibits the tissue tropism and associates with the altered susceptibility of patients.

At the evolutionary side, RBD of S-protein shows 73% similarity between SARS-CoV-1 and SARS-CoV-2. Of note, most of the positively charged residues at the RBD surface are conserved between them, except the Lys444 in SARS-CoV-2, which is a Thr in SARS-CoV-1. While, in other conserved residues, Asn354 existed in SARS-CoV-2 that is originally a negatively charged Glu in SARS-CoV-1. Clausen et al. 1 suggested that these 2 substitutions of Thr → Lys444 and Glu → Asn354 from SARS-CoV-1 to SARS-CoV-2 potentially evolved the electropositive affinity of RBD to HS that was reflected in their enhanced interaction in SARS-CoV-2. In agreement this, SARS-CoV-2-recombinant RBD protein exhibited a stronger affinity with heparin-bovine serum albumin, as compared to SARS-CoV-1. A recent report by Kim et al. 3 also corroborated this finding by showing that immobilized heparin binds more strongly to the SARS-CoV-2 monomeric and trimeric S-protein than that of the SARS-CoV and MERS-CoV.

Lang et al. 4 earlier showed that SARS-CoV-1 besides its entry receptors ACE2 and the transmembrane protease serine 2 (TMPRSS2) also establishes contact with HS at the cell surface. Here, Clausen et al. 1 demonstrated that how a stretch of positively charged residues at the RBD domain establishes a strong interaction with HS, thereby, affirming how the electropositive affinity of RBD evolved from SARS-CoV-1 to SARS-CoV-2. Moreover, it revealed that HS and heparin compete for the SARS-CoV-2 S-protein RBD binding, while an inhibitory effect of heparin on pseudovirus and authentic SARS-CoV-2 infectivity was observed. 1 To order to assess the specificity of HS interaction with SARS-CoV-2 S-protein, a study by Kim et al. 3 analyzed the competitive binding kinetics of S-protein with another glycosaminoglycan (GAGs), including different chondroitin sulfates, dermatan, and keratan sulfates, revealing weak or no binding activities of these GAGs. It, therefore, suggested that among different GAGs, HS interaction with SARS-CoV-2 protein is highly specific. Also, they showed that the sulfate groups within heparin have a critical impact on its interaction with SARS-CoV-2 Sprotein as the chemically modified heparins lacked a competitive binding to the latter. 3 While analyzing the antiviral properties of heparin-related GAGs and sulfated polysaccharides in vitro, Kwon et al. 5 further reaffirmed specific sulfonated heparin binding to Sprotein and suggested their therapeutic utility for COVID-19 patients in the clinics. Taken together, Clausen et al. 1 and these reports underlined the therapeutic potential of heparins (unfractionated heparin (UFH), non-anticoagulant heparin, and heparin lyases) by competing/targeting the pseudotyped virus or authentic SARS-CoV-2 interaction with HS to control SARS-CoV-2 infection and spread. [3] [4] [5] Thrombotic complications are unrealistically frequent in COVID-19 patients. These include cardiac thrombosis, vascular or disseminated intravascular microthromboses, venous thromboembolism, and stroke, limb/mesenteric ischemia and therefore frequently treated with therapeutic UFH or low-molecular-weight heparin (LMWH). Here, Clausen et al. 1 further identified that the anticoagulant function of heparin (lacking in HS) is independent of its viral-inhibitory activity. These results corroborated therapeutics usage of UFH and LMWH against SARS-CoV-2 infection, essentially by inhibiting the Sprotein binding to the cell. 1,3-5 Although findings by Clausen et al. provided insights into the role of HS in SARS-CoV-2 infection, further research is warranted to exercise its therapeutic potential in clinics. Also, these results stress the necessity to delineate the antiviral or anticoagulant efficacy and dosage of heparin and non-anticoagulant heparins in the clinic against COVID-19.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons. 

SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Characterization of heparin and severe acute respiratory syndromerelated coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions. Antiviral Res

Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans

Sulfated polysaccharides effectively inhibit SARS-CoV-2 in vitro

R.K. acknowledged Dr. Chandrasekhar Srivari, Director, and Dr. Prathama S Mainkar CSIR-IICT, Hyderabad, India for the manuscript preparion. R.S.K. and R.K. conceived the idea and wrote the paper.

Competing interests: The authors declare no competing interests.